Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Hicks

Nurse Practitioner Muncie, IN Nurse Practitioner

NPI 1912147943 CMS profile 11016215

401 W McGalliard Rd, Muncie, IN 47303

Open in the dashboard

General payments

$5,763

395 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Hicks of Muncie, IN is reported in the CMS Open Payments database as having received $5,763 across 395 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $980 43
2024 General $1,195 84
2023 General $1,135 72
2022 General $1,211 103
2021 General $1,242 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Hicks
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Michelle Hicks were reported at $980. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Michelle Hicks Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,242 $135 $40–$426 $132
2022 $1,211 $152 $48–$470 $149
2023 $1,135 $166 $54–$529 $160
2024 $1,195 $173 $55–$556 $164
2025 $980 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $994 79 payments
  2. Janssen Biotech, Inc. $835 78 payments
  3. Sun Pharmaceutical Industries Inc. $772 39 payments
  4. Novartis Pharmaceuticals Corporation $698 76 payments
  5. Genzyme Corporation $316 12 payments
  6. Pfizer Inc. $314 19 payments
  7. LEO Pharma Inc. $275 16 payments
  8. Lilly USA, LLC $272 17 payments
  9. Incyte Corporation $237 14 payments
  10. UCB, Inc. $208 11 payments
  11. Other $841 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,473 391 payments
  2. Education $290 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $785 74 payments
  2. SKYRIZI $489 43 payments
  3. DUPIXENT $466 15 payments
  4. RINVOQ $451 33 payments
  5. ILUMYA $447 26 payments
  6. TALTZ $272 17 payments
  7. COSENTYX $254 26 payments
  8. OPZELURA $237 14 payments
  9. CIBINQO $237 14 payments
  10. EUCRISA $222 13 payments
  11. Other $2,686 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,855

Median for Nurse Practitioner: 389

Drug cost

$882,201

Median for Nurse Practitioner: $21,885

Branded share of claims

8.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 24 $324,348
Skyrizi Risankizumab-Rzaa Brand 15 $320,793
Dupixent Pen Dupilumab Brand 37 $136,767
Dupixent Syringe Dupilumab Brand 16 $58,037
Fluorouracil Generic 91 $6,375
Clobetasol Propionate Generic 126 $6,133
Ketoconazole Generic 288 $5,563
Triamcinolone Acetonide Generic 397 $3,667
Metronidazole Generic 67 $3,328
Fluocinonide Generic 96 $3,206

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$273,303

Of which drugs: $113,034

Medicare patients

1,469

Average age 75

Services billed

6,529

908 women, 561 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 43%
Diabetes 26%
Ischemic heart disease 23%
Chronic kidney disease 21%
Depression 21%
Osteoporosis 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 18 $5,238
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 66 $45

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $172
$172 — —
TREMFYA
  • Janssen Biotech, Inc. $144
$144 24 —
RINVOQ
  • AbbVie, Inc. $132
$132 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $121
$121 — —
DUPIXENT
  • GENZYME CORPORATION $90
$90 53 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record